基于转录的 COVID-19 药物再利用。

Transcription-based drug repurposing for COVID-19.

机构信息

Maurice Wohl Clinical Neuroscience Institute, King's College London, UK.

University of Exeter Medical School, College of Medicine and Health, University of Exeter, UK.

出版信息

Virus Res. 2020 Dec;290:198176. doi: 10.1016/j.virusres.2020.198176. Epub 2020 Sep 25.

DOI:10.1016/j.virusres.2020.198176

PMID:32987033

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7518800/

Abstract

We have utilised the transcriptional response of lung epithelial cells following infection by the original Severe Acute Respiratory Syndrome coronavirus (SARS) to identify repurposable drugs for COVID-19. Drugs best able to recapitulate the infection profile are highly enriched for antiviral activity. Nine of these have been tested against SARS-2 and found to potently antagonise SARS-2 infection/replication, with a number now being considered for clinical trials. It is hoped that this approach may serve to broaden the spectrum of approved drugs that should be further assessed as potential anti-COVID-19 agents and may help elucidate how this seemingly disparate collection of drugs are able to inhibit SARS-2 infection/replication.

摘要

我们利用肺上皮细胞在感染原始严重急性呼吸系统综合症冠状病毒（SARS）后的转录反应，来鉴定可用于治疗 COVID-19 的可再利用药物。最能重现感染特征的药物对抗病毒活性高度富集。其中有 9 种药物已针对 SARS-2 进行了测试，发现它们能有效拮抗 SARS-2 的感染/复制，其中一些目前正在考虑进行临床试验。希望这种方法可以扩大已批准药物的范围，这些药物应进一步评估为潜在的抗 COVID-19 药物，并有助于阐明这些看似不同的药物是如何抑制 SARS-2 的感染/复制的。